Allurion Technologies announces new clinical data on the Allurion Program presented at ObesityWeek 2021.

The Allurion Program is a 360-degree weight loss experience featuring the Allurion Balloon, a swallowable, procedureless gastric balloon for weight loss, remote patient monitoring through the Allurion Virtual Care Suite including the Allurion Connected Scale, Health Tracker, and App, and Allurion Insights, a provider portal that enables message, telehealth, and end-to-end patient management.

Despite the availability of pharmacologic therapies for Type 2 Diabetes, the incidence of metabolic disease continues to rise around the world.

“Obesity and Type 2 Diabetes are pandemics of unprecedented magnitude, and they often afflict patients simultaneously. Current treatments for obesity and diabetes either suffer from poor safety and efficacy or a poor patient experience. The Allurion Program offers a compelling alternative for the treatment of both of these conditions.”

– Dr. Shantanu Gaur, co-founder and CEO of Allurion

Helps Put Diabetes Into Remission?

In an abstract submitted and accepted for presentation at ObesityWeek 2021 titled Allurion Gastric Balloon Program is an Emerging Novel Treatment for Type 2 Diabetes and Prediabetes, Dr. Roberta Ienca and colleagues report on 226 patients (78 with Type 2 Diabetes and 148 with prediabetes) who enrolled in the Allurion Program and were followed for a period of 4 months. After 4 months, mean hemoglobin A1c (HbA1c) decreased from 7.0% to 5.5% with a mean weight loss of 19.3kg in patients with diabetes.

Remission of diabetes is typically defined as lowering HbA1c to below 6.5%, indicating that the average patient in the diabetes group achieved remission after just 4 months. In patients with prediabetes, mean HbA1c decreased from 6.0% to 4.9% with a mean weight loss of 16.9kg.

“The Allurion Program provides patients with an effective tool to reduce HbA1c and put Type 2 Diabetes into remission. These results underscore the benefits of the Allurion Program beyond weight loss and highlight how quickly the Allurion Program can have an impact on patients with Type 2 Diabetes or prediabetes.”

— Dr. Ram Chuttani, Chief Medical Officer of Allurion

[Source(s): Allurion Technologies, Business Wire]

Related Content:
Allurion Technologies Launches Allurion Insights Solution for Weight-Loss Providers
Allurion Technologies Launches New Weight Loss Program and Branding
Allurion Technologies Announces 5 Million Pound Challenge in Celebration of World Obesity Day